Next-generation probiotics - do they open new therapeutic strategies for cancer patients?

Gut microbiota and its association with cancer development/treatment has been intensively studied during the past several years. Currently, there is a growing interest toward next-generation probiotics (NGPs) as therapeutic agents that alter gut microbiota and impact on cancer development. In the pr...

Full description

Saved in:
Bibliographic Details
Published in:Gut microbes 2022-12, Vol.14 (1), p.2035659-2035659
Main Authors: Kaźmierczak-Siedlecka, Karolina, Skonieczna-Żydecka, Karolina, Hupp, Theodore, Duchnowska, Renata, Marek-Trzonkowska, Natalia, Połom, Karol
Format: Article
Language:English
Subjects:
Akkermansia muciniphila
Animals
Antineoplastic Agents - administration & dosage
Bacteroides fragilis
cancer
Combined Modality Therapy
Faecalibacterium prausnitzii
Gastrointestinal Microbiome
Gastrointestinal Tract - immunology
Gastrointestinal Tract - microbiology
Gut microbiota
Humans
immunotherapy
Neoplasms - drug therapy
Neoplasms - immunology
Neoplasms - microbiology
Neoplasms - radiotherapy
next-generation probiotics
Probiotics - administration & dosage
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gut microbiota and its association with cancer development/treatment has been intensively studied during the past several years. Currently, there is a growing interest toward next-generation probiotics (NGPs) as therapeutic agents that alter gut microbiota and impact on cancer development. In the present review we focus on three emerging NGPs, namely Faecalibacterium prausnitzii, Akkermansia muciniphila, and Bacteroides fragilis as their presence in the digestive tract can have an impact on cancer incidence. These NGPs enhance gastrointestinal immunity, maintain intestinal barrier integrity, produce beneficial metabolites, act against pathogens, improve immunotherapy efficacy, and reduce complications associated with chemotherapy and radiotherapy. Notably, the use of NGPs in cancer patients does not have a long history and, although their safety remains relatively undefined, recently published data has shown that they are non-toxigenic. Notwithstanding, A. muciniphila may promote colitis whereas enterotoxigenic B. fragilis stimulates chronic inflammation and participates in colorectal carcinogenesis. Nevertheless, the majority of B. fragilis strains provide a beneficial effect to the host, are non-toxigenic and considered as the best current NGP candidate. Overall, emerging studies indicate a beneficial role of these NGPs in the prevention of carcinogenesis and open new promising therapeutic options for cancer patients.
ISSN:1949-0976
1949-0984
DOI:10.1080/19490976.2022.2035659